871 related articles for article (PubMed ID: 16795933)
1. International Conference on Harmonisation; guidance on Q9 Quality Risk Management; availability. Notice.
Food and Drug Administration, HHS
Fed Regist; 2006 Jun; 71(106):32105-6. PubMed ID: 16795933
[TBL] [Abstract][Full Text] [Related]
2. International Conference on Harmonisation; guidance on Q10 Pharmaceutical Quality System; availability. Notice.
Food and Drug Administration, HHS
Fed Regist; 2009 Apr; 74(66):15990-1. PubMed ID: 19507321
[TBL] [Abstract][Full Text] [Related]
3. International Conference on Harmonisation; guidance on electronic common technical document specification; availability. Notice.
Food and Drug Administration, HHS
Fed Regist; 2003 Apr; 68(63):16060-1. PubMed ID: 12674113
[TBL] [Abstract][Full Text] [Related]
4. International Conference on Harmonisation; guidance on E2E Pharmacovigilance Planning; availability. Notice.
Food and Drug Administration, HHS
Fed Regist; 2005 Apr; 70(62):16827-8. PubMed ID: 15803631
[TBL] [Abstract][Full Text] [Related]
5. International Conference on Harmonisation; guidance on good manufacturing practice for active pharmaceutical ingredients; availability. Notice.
Food and Drug Administration, HHS
Fed Regist; 2001 Sep; 66(186):49028-9. PubMed ID: 12358036
[TBL] [Abstract][Full Text] [Related]
6. International Conference on Harmonisation; guidance on Q5E Comparability of Biotechnological/Biological Products Subject to Changes in Their Manufacturing Process; availability. Notice.
Food and Drug Administration, HHS
Fed Regist; 2005 Jun; 70(125):37861-2. PubMed ID: 15988855
[TBL] [Abstract][Full Text] [Related]
7. International Conference on Harmonisation; revised guidance on Q3B(R) Impurities in New Drug Products; Availability. Notice.
Food and Drug Administration, HHS
Fed Regist; 2003 Nov; 68(220):64628-9. PubMed ID: 14619944
[TBL] [Abstract][Full Text] [Related]
8. International Conference on Harmonisation; Guidance on S8 Immunotoxicity Studies for Human Pharmaceuticals; availability. Notice.
Food and Drug Administration, HHS
Fed Regist; 2006 Apr; 71(71):19193-4. PubMed ID: 16612859
[TBL] [Abstract][Full Text] [Related]
9. International Conference on Harmonisation: guidance on Q1D bracketing and matrixing designs for stability testing of new drug substances and products; availability. Notice.
Food and Drug Administration, HHS
Fed Regist; 2003 Jan; 68(11):2339-40. PubMed ID: 12532979
[TBL] [Abstract][Full Text] [Related]
10. International Conference on Harmonisation; guidance on specifications: test procedures and acceptance criteria for biotechnological/biological products. Notice. Food and Drug Administration, HHS.
Fed Regist; 1999 Aug; 64(159):44928-35. PubMed ID: 12356094
[TBL] [Abstract][Full Text] [Related]
11. International Conference on Harmonisation; guidance on Q4B Evaluation and Recommendation of Pharmacopoeial Texts for use in the International Conference on Harmonisation Regions; Annex 4C on Microbiological Examination of Nonsterile Products: Acceptance Criteria for Pharmaceutical Preparations and Substances for Pharmaceutical Use General Chapter; availability. Notice.
Food and Drug Administration, HHS
Fed Regist; 2009 Apr; 74(66):15992-3. PubMed ID: 19507323
[TBL] [Abstract][Full Text] [Related]
12. International Conference on Harmonisation; guidance on S7A safety pharmacology studies for human pharmaceuticals; availability. Notice.
Food and Drug Administration, HHS
Fed Regist; 2001 Jul; 66(135):36791-2. PubMed ID: 12356097
[TBL] [Abstract][Full Text] [Related]
13. International Conference on Harmonisation; evaluation of stability data; availability. Notice.
Food and Drug Administration, HHS
Fed Regist; 2004 Jun; 69(110):32010-1. PubMed ID: 15185712
[TBL] [Abstract][Full Text] [Related]
14. International Conference on Harmonisation; guidance on quality of biotechnological/biological products: derivation and characterization of cell substrates used for production of biotechnological/biological products; availability. Notice. Food and Drug Administration, HHS.
Fed Regist; 1998 Sep; 63(182):50244-9. PubMed ID: 12269373
[TBL] [Abstract][Full Text] [Related]
15. International Conference on Harmonisation; revised guidance on Q3A impurities in new drug substances; availability. Notice.
Food and Drug Administration, HHS
Fed Regist; 2003 Feb; 68(28):6924-5. PubMed ID: 12583358
[TBL] [Abstract][Full Text] [Related]
16. International Conference on Harmonisation; guidance on Q8(R1) Pharmaceutical Development; addition of annex; availability. Notice.
Food and Drug Administration, HHS
Fed Regist; 2009 Jun; 74(109):27325-6. PubMed ID: 19588572
[TBL] [Abstract][Full Text] [Related]
17. International Conference on Harmonisation; guidance on Addendum to E2C Clinical Safety Data Management: Periodic Safety Update Reports for Marketed Drugs; availability. Notice.
Food and Drug Administration, HHS
Fed Regist; 2004 Feb; 69(24):5551-2. PubMed ID: 14968802
[TBL] [Abstract][Full Text] [Related]
18. International Conference on Harmonisation; Guidance on Q8 Pharmaceutical Development; availability. Notice.
Food and Drug Administration, HHS
Fed Regist; 2006 May; 71(98):29344-5. PubMed ID: 16749216
[TBL] [Abstract][Full Text] [Related]
19. International Conference on Harmonisation; guidance on E11 clinical investigation of medicinal products in the pediatric population; availability. Notice.
Food and Drug Administration, HHS
Fed Regist; 2000 Dec; 65(242):78493-4. PubMed ID: 12362934
[TBL] [Abstract][Full Text] [Related]
20. International Conference on Harmonisation; addendum to International Conference on Harmonisation Guidance on S6 Preclinical Safety Evaluation of Biotechnology-Derived Pharmaceuticals; availability. Notice.
Food and Drug Administration, HHS
Fed Regist; 2012 May; 77(97):29665-6. PubMed ID: 22616137
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
